FDA Approves First Treatment for Sanfilippo Syndrome Type A
The FDA approved Fayuvi as the first treatment for Sanfilippo syndrome type A. This gene therapy targets an ultra-rare disease population. The treatment is newly approved, so long-term outcomes and real-world effectiveness are still to be determined. Pricing has not yet been announced.
Why it matters
This approval provides the first treatment option for patients with a genetic condition that previously had none.
CHECKED · 1 SOURCE · UNCORROBORATED
← All news